{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T04:21:39Z","timestamp":1787631699895,"version":"build-2736575974"},"reference-count":13,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,7,9]],"date-time":"2016-07-09T00:00:00Z","timestamp":1468022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Up to 70% of patients receiving hematopoietic stem cell transplant develop oral mucositis as a side effect of high-dose melphalan conditioning chemotherapy. Oral cryotherapy has been documented to be potentially effective in reducing oral mucositis. The aim of this study was to examine the effectiveness of the cryotherapy protocol implemented within the hematopoietic stem cell transplant program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted of adult multiple myeloma patients who received high-dose melphalan conditioning therapy for autologous hematopoietic stem cell transplant. Primary endpoints were incidence and severity of oral mucositis. Secondary endpoints included duration of oral mucositis, duration of hospital stay, parenteral narcotics use and total parenteral nutrition use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and forty patients were included in the study, 70 patients in both no cryotherapy and cryotherapy groups. Both oral mucositis incidence and severity were found to be significantly lower in the cryotherapy group. Fifty (71.4%) experienced mucositis post cryotherapy compared to 67 (95.7%) in the no cryotherapy group (p\u2009&lt;\u20090.001). The median oral mucositis severity, assessed using the WHO oral toxicity scale from grade 0\u20134, experienced in the no group was 2.5 vs. 2 in the cryotherapy group (p\u2009=\u20090.03). Oral mucositis duration and use of parenteral narcotics were also significantly reduced. Duration of hospital stay and use of parenteral nutrition were similar between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The cryotherapy protocol resulted in a significantly lower incidence and severity of oral mucositis. These results provide evidence for the continued use of oral cryotherapy, an inexpensive and generally well-tolerated practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155215620920","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T21:37:44Z","timestamp":1450474664000},"page":"116-120","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant"],"prefix":"10.1177","volume":"23","author":[{"given":"Joey","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Alberta Health Services, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Seabrook","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, London Health Sciences Center, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Fulford","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, London Health Sciences Center, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Rajakumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, London Health Sciences Center, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,7,9]]},"reference":[{"key":"bibr1-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-012-1562-0"},{"key":"bibr2-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22484"},{"key":"bibr3-1078155215620920","first-page":"193","volume-title":"Putting evidence into practice: improving oncology patient outcomes","author":"Harris DJ","year":"2009"},{"key":"bibr4-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.2005.01128.x"},{"key":"bibr5-1078155215620920","first-page":"CD000978","volume":"26","author":"Worthington HV","year":"2010","journal-title":"Cochrane Database System Rev"},{"key":"bibr6-1078155215620920","unstructured":"Harle I.\n                      Cancer care Ontario\u2019s symptom management guide-to-practice: oral care\n                      . Toronto ON, July 2012, pp. 13\u201317. Available at: https:\/\/www.google.ca\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0ahUKEwi2_OehqcrJAhVwpYMKHbjkAEAQFggiMAE&url=https%3A%2F%2Fwww.cancercare.on.ca%2FCCO_DrugFormulary%2FPages%2FFileContent.aspx%3FfileId%3D154813&usg=AFQjCNHCyEdxMFGz0dc12GAJATTV2IW4Ew&sig2=o1R8YzEqWTYE3IOcevMkEA&bvm=bv.108538919,d.amc."},{"key":"bibr7-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-004-0726-y"},{"key":"bibr8-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705384"},{"key":"bibr9-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705494"},{"key":"bibr10-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12386"},{"key":"bibr11-1078155215620920","unstructured":"National Cancer Institute, surveillance, epidemiology, and end results. Fast stats. Cancer stat fact sheets, http:\/\/seer.cancer.gov\/faststats\/ (accessed 25 October 2015)."},{"key":"bibr12-1078155215620920","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13782"},{"key":"bibr13-1078155215620920","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21913"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215620920","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215620920","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215620920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:33Z","timestamp":1777688193000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215620920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,9]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1177\/1078155215620920"],"URL":"https:\/\/doi.org\/10.1177\/1078155215620920","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,9]]}}}